ArticleJournal of diabetes and metabolic disorders2022
Mapping research in diabetes complications; A scoping review.
Article in Journal of diabetes and metabolic disorders, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: The study goal was to report research gaps in this field of diabetes complications in the past five years in Iran. Methods: All diabetes research outputs by Iranians from Jan 2015 to Jan 2020 were retrieved by a comprehensive search in Scopus and Pubmed. After screening, remained documents were categorized into areas including complications, comorbidity, prevention, psychology, nutrition, physical activity, treatment, and gestational diabetes mellitus (GDM). Results: 838 documents about complications were received and among the remained records, the most common topics respectively were about microvascular (44.99%), non-vascular complications (19.13%) and macrovascular (16.74%) complications. Regarding the level of evidence the most common studies were respectively animal studies (68%), case-control (57%) and randomized clinical trial (RCT) (39%). Conclusions: The most common topics studied in Iran in the field of diabetes complication are microvascular compilations followed by non-vascular and macrovascular complications, respectively.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.